Research programme: antibacterial therapeutics - Enbiotix

Drug Profile

Research programme: antibacterial therapeutics - Enbiotix

Alternative Names: Amikacin + bacterial metabolite - EnBIotix; Amikacin + potentiator - EnBIotix; EBX 001; EBX 002; EPP 001

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EnBiotix
  • Class Aminoglycosides; Antibacterials
  • Mechanism of Action Bacteria replacements; Bacterial growth modulators; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Pseudomonal infections; Urinary tract infections

Most Recent Events

  • 13 Jun 2016 EnBiotix enters a co-development agreement with Mayo Clinic for the development of EPP 001
  • 24 May 2016 EnBiotix plans a phase I/IIa trial for Urinary tract infections and Pseudomonal infections in USA (EnBiotix corporate presentation, May 2016)
  • 12 May 2016 EnBiotix candidates licensed to EnBiotix Brasil in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top